Disclosed herein is the use of the aromatase inhibitor 4,4’-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile in the manufacture of a medicament for the treatment of hypogonadism in a male patient with serum total testosterone levels below 400 ng/dl, wherein the compound is provided in a form comprising from about 0.001 mg to about 1.0 mg 4,4’-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile per dose.